Aurobindo Pharma Limited — Important, 18-02-2025: Updates

The US FDA conducted a Pre-Approval Inspection (PAI) at Eugia Steriles Private Limited, a 100% subsidiary of Aurobindo Pharma, from February 10 to February 18, 2025. The inspection concluded with five procedural observations, which the company plans to address within the prescribed timeframe. While the observations are not expected to hinder operations significantly, it is crucial for investors to watch closely for updates on the company's response. This inspection reflects Aurobindo's ongoing commitment to maintaining compliance and quality standards in its manufacturing processes.